Decrease of neurofilament is associated with reduction of clinical disease activity in glatiramer acetate treated people with multiple sclerosis

被引：0
|
作者：
Konofalska, U. [1 ]
Akgun, K. [1 ]
Proschmann, U. [1 ]
Haase, R. [2 ]
Ziemssen, T. [1 ]
机构：
[1] Tech Univ Dresden, Carl Gustav Carus Univ Hosp, Dept Neurol, Ctr Clin Neurosci, Dresden, Germany
[2] Tech Univ Dresden, Carl Gustav Carus Univ Hosp, Ctr Clin Neurosci, Dresden, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P599
引用
收藏
页码：526 / 527
页数：2
相关论文
共 50 条
  • [41] Fatigue in relapsing-remitting multiple sclerosis - assessment of clinical, neuropsychological and immunological parameters in patients treated with glatiramer acetate
    Neuhaus, Oliver
    Dehmel, Thomas
    Kieseier, Bernd
    Hartung, Hans-Peter
    MULTIPLE SCLEROSIS, 2008, 14 : S169 - S169
  • [42] JNK and phosphorylated Bcl-2 predict multiple sclerosis clinical activity and glatiramer acetate therapeutic response
    Anselmo, Freidrich
    Tatomir, Alexandru
    Boodhoo, Dallas
    Mekala, Armugam P.
    Vinh Nguyen
    Rus, Violeta
    Rus, Horea
    CLINICAL IMMUNOLOGY, 2020, 210
  • [43] De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate
    Havla, Joachim
    Gerdes, Lisa Ann
    Meinl, Ingrid
    Krumbholz, Markus
    Faber, Hans
    Weber, Frank
    Pellkofer, Hannah Luise
    Hohlfeld, Reinhard
    Kuempfel, Tania
    JOURNAL OF NEUROLOGY, 2011, 258 (09) : 1665 - 1669
  • [44] De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate
    Joachim Havla
    Lisa Ann Gerdes
    Ingrid Meinl
    Markus Krumbholz
    Hans Faber
    Frank Weber
    Hannah Luise Pellkofer
    Reinhard Hohlfeld
    Tania Kümpfel
    Journal of Neurology, 2011, 258 : 1665 - 1669
  • [45] SIRT1 as a potential marker of disease activity and response to treatment with Glatiramer Acetate in multiple sclerosis.
    Hewes, Daniel
    Tatomir, Alexandru
    Kruszewski, Adam M.
    Criello, Jonathan
    Rao, Gautam K.
    Royal, Walter, III
    Bever, Christopher T.
    Rus, Horea
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 14 - 14
  • [46] Long-term treatment of multiple sclerosis patients with glatiramer acetate: clinical efficacy and anti-glatiramer acetate antibodies profile
    Teitelbaum, D.
    Brenner, T.
    Abramsky, O.
    Sicsic, C.
    Arnon, R.
    Karussis, D.
    MULTIPLE SCLEROSIS, 2006, 12 : S98 - S99
  • [47] Does First Year MRI and Clinical Activity Correlate with Long Term Clinical Response to Glatiramer Acetate in Multiple Sclerosis Patients?
    Karmon, Yuval
    Ramanathan, Murali
    Weinstock-Guttman, Bianca
    NEUROLOGY, 2013, 80
  • [48] Clinical Validation of a Novel In Vitro Diagnostic Neurofilament Light Chain Assay for the Prognostication of Disease Activity in People with Relapsing Multiple Sclerosis
    Freedman, Mark S.
    Ziemssen, Tjalf
    Bar-Or, Amit
    Montalban, Xavier
    Teunissen, Charlotte
    Haring, Dieter
    Kukkaro, Petra
    Merschhemke, Martin
    Kieseier, Bernd C.
    Karnik-Henry, Meghana
    Gee, Matthew
    Lange, Sascha
    Merabet, Eddine
    Chitnis, Tanuja
    Bittner, Stefan
    Wiendl, Heinz
    Hauser, Stephen
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1238 - 1239
  • [49] Idiopathic thrombocytopenic purpura associated with glatiramer acetate in a multiple sclerosis patient: case report
    Turan, OF
    Taskapilioglu, MO
    Taskapilioglu, O
    Ozkocaman, V
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S257 - S257
  • [50] Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years
    Chen, M
    Conway, K
    Johnson, KP
    Martin, R
    Dhib-Jalbut, S
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2002, 201 (1-2) : 71 - 77
12345